>Cellular immunity is highly durable and effective.
The question is not how long the immunity lasts (based on original SARS patients, probably multiple decades to a lifetime), but whether affinity-matured T-cells can sufficiently cover the antigen-space of future ACE2-binding spike proteins.
Somatic hypermutation might still be too complex to model computationally to answer that question outright.
Do you know whether this question is answerable in another way?
The question is not how long the immunity lasts (based on original SARS patients, probably multiple decades to a lifetime), but whether affinity-matured T-cells can sufficiently cover the antigen-space of future ACE2-binding spike proteins.
Somatic hypermutation might still be too complex to model computationally to answer that question outright.
Do you know whether this question is answerable in another way?